INVIRAGEN
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.
INVIRAGEN
Industry:
Biotechnology Health Care Medical
Founded:
2003-01-01
Address:
Fort Collins, Colorado, United States
Country:
United States
Website Url:
http://www.inviragen.com
Total Employee:
11+
Status:
Active
Contact:
9703720693
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
IPv6 Google Apps For Business Cloudflare Hosting Cloudflare DNS
Similar Organizations
Henry Ford Health System
Henry Ford Health System (HFHS) is one of the nationโs leading comprehensive, integrated health systems.
Current Advisors List
Investors List
Charter Life Sciences
Charter Life Sciences investment in Series A - Inviragen
EDBI
EDBI investment in Series A - Inviragen
Phillip Private Equity
Phillip Private Equity investment in Series A - Inviragen
Venture Investors
Venture Investors investment in Series A - Inviragen
Official Site Inspections
http://www.inviragen.com
- Host name: 104.21.3.4
- IP address: 104.21.3.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inviragen"
Inviragen, Inc. - Org Chart, Teams, Culture & Jobs | The Org
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a โฆSee details»
Inviragen Company Profile 2024: Valuation, Investors, Acquisition ...
Inviragen General Information Description. Developer of vaccines to protect against various infectious diseases. The company offers its products to protect against dengue viruses, as well โฆSee details»
Inviragen, Inc. Overview | SignalHire Company Profile
Inviragen, Inc. is a private company that has been in the industry for 19 years. The company currently specializes in the Pharmaceuticals area. ... Organization Website. inviragen.com . โฆSee details»
Inviragen, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Last update 19 Sep 2024. Inviragen, Inc. Private Company |See details»
Inviragen Inc., Dan Stinchcomb, - walkersresearch.com
[email protected]: Phone: 1-970-372-4754: Website: www.inviragen.com Fax: 1-970-372-0693: Summary ; Executive Details ; Board Members ; Business Information The group's principal โฆSee details»
Takeda Pharmaceuticals North America, Inc.
Inviragen has created innovative products using its expertise in viral vaccines. The companyโs lead candidate, DENVax, is a four-strain recombinant viral vaccine for the prevention of โฆSee details»
Inviragen Inc - Company Profile and News - Bloomberg Markets
Inviragen, Inc. develops life-saving vaccines to protect against various infectious diseases. The Company offers products to protect against dengue viruses, as well as swine-origin, โฆSee details»
Inviragen - Company Profile - Tracxn
Dec 14, 2024 Inviragen - Developer of vaccines for infectious diseases. Acquired by Takeda. Raised a total funding of $15.3M over 2 rounds from 4 investors. Inviragen has 428 competitors.See details»
Inviragen - Ownership and Business Overview - Mergr
May 8, 2013 Inviragen was founded in 2003. Healthcare Services M&A Summary in 2013. Out of 60 sectors in the Mergr database, healthcare services ranked 5 in number of deals in 2013. โฆSee details»
Inviragen - Products, Competitors, Financials, Employees, โฆ
About Inviragen. Inviragen develops life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's product candidates included a vaccine to protect against โฆSee details»
Inviragen - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 6, 2009: Series A - โฆSee details»
Inviragen, Inc. (Inviragen, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
These vaccines are supplied annually for use in the Expanded Program on Immunization and for domestic needs. For more information, please visit About Inviragen, Inc. Inviragen is focused โฆSee details»
Inviragen - PharmaBoardroom
Feb 13, 2014 Inviragen is addressing unmet needs in this growing global vaccine marketplace. The company has created a team of dedicated vaccine development specialists in the United โฆSee details»
Inviragen - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Inviragen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Number of Board Member and Advisor โฆSee details»
Inviragen โ Venture Investors
Sep 7, 2016 Together with Charter Life Sciences, Venture Investors pledged the support that enabled Inviragen to reach a merger agreement with Singapore based SingVax. This support โฆSee details»
Takeda to Acquire Inviragen - PE Hub
May 8, 2013 Inviragen has also developed a recombinant vaccine candidate to protect against chikungunya, currently in preclinical development. ... and is one of four World Health โฆSee details»
Takeda to acquire Inviragen for $35m - pharmaphorum
May 8, 2013 Inviragen's lead candidate, DENVax, is a four-strain recombinant viral vaccine for the prevention of dengue infection, which is currently being evaluated in phase 2 clinical trials.See details»
Inviragen - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Inviragen uses 6 technology products and services including HTML5, jQuery, and Apache Server, according to G2 Stack. Inviragen is actively using 22 technologies for its website, according to โฆSee details»
Takeda buys vaccines specialist Inviragen - PMLiVE
May 8, 2013 Takeda has gained the rights to vaccines candidates against emerging infectious diseases, including dengue and hand, foot and mouth disease, as part of a $250m deal to โฆSee details»